Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors

Nature Biotechnology

Volumn 21, Issue 9, 2003, Pages 1040-1046

  Müller, Oliver J ^a   Kaul, Felix ^b   Weitzman, Matthew D ^c   Pasqualini, Renata ^d   Arap, Wadih ^d   Kleinschmidt, Jürgen A ^a   Trepel, Martin ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENES; SURFACES; VIRUSES;

LIGANDS;

BIOTECHNOLOGY;

ADENOVIRUS VECTOR; PEPTIDE LIBRARY;

ADENOVIRUS 2; AMINO ACID SEQUENCE; ARTERY ENDOTHELIUM; ARTICLE; BIOTECHNOLOGY; CELL SURFACE; CELL TYPE; CORONARY ARTERY; DNA PACKAGING; GENE TARGETING; GENETIC CODE; LIGAND BINDING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PARTICLE;

AMINO ACID SEQUENCE; CAPSID; CELLS, CULTURED; CORONARY VESSELS; DEPENDOVIRUS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, VIRAL; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; SEQUENCE ANALYSIS, PROTEIN; TRANSDUCTION, GENETIC; VIRAL PROTEINS;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; EUKARYOTA; EUKARYOTIC VECTORS; HUMAN ADENOVIRUS TYPE 2;

EID: 0042360384     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt856     Document Type: Article

References (46)

1. Somia, N. & Verma, I.M. Gene therapy: trials and tribulations. Nat. Rev. Genet. 1, 91-99 (2000).
2. McCormick, F. Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer 1, 130-141 (2001).
3. Marshall, E. Gene therapy a subject in leukemia-like disease. Science 298, 34-35 (2002).
4. Wickham, T.J. Targeting adenovirus, Gene Ther. 7, 110-114 (2000).
5. Trepel, M., Arap, W. & Pasqualini, R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr. Opin. Chem. Biol. 6, 399-404 (2002).
6. Larochelle, A., Peng, K.W. & Russell, S.J. Lentiviral vector targeting. Curr. Top. Microbiol. 261, 143-163 (2002).
7. Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366 (1996).
8. Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121-127 (2002).
9. Barry, M.A., Dower, W.J. & Johnston, S.A. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med. 2, 299-305 (1996).
10. Laakkonen, P., Porkka, K., Hoffman, J.A. & Ruoslahti, E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8, 751-755 (2002).
11. Trepel, M., Arap, W. & Pasqualini, R. Modulation of the immune response by systemic targeting of antigens to lymph nodes. Cancer Res. 61, 8110-8112 (2001).
12. Ellerby, H.M. et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5, 1032-1038 (1999).
13. Curnis, F. et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18, 1185-1190 (2000).
14. Bartlett, J.S., Kleinschmidt, J., Boucher, R.C. & Samulski, R.J. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab gamma)(2) antibody. Nat. Biotechnol. 17, 181-186 (1999).
15. Reynolds, P.N. et al. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol. Ther. 2, 562-578 (2000).
16. Nettelbeck, D.M. et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol. Ther. 3, 882-891 (2001).
17. Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J. & Castillas, J.M.J. Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J. Virol. 76, 12900-12907 (2002).
18. Trepel, M., Grifman, M., Weitzman, M.D. & Pasqualini, R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum. Gene Ther. 11, 1971-1981 (2000).
19. Nicklin, S.A. et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174-181 (2001).
20. Grifman, M. et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964-975 (2001).
21. Monahan, P.E. & Samulski, R.J. AAV vectors: is clinical success on the horizon? Gene Ther. 7, 24-30 (2000).
22. Summerford, C. & Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445 (1998).
23. Summerford, C., Bartlett, J.S. & Samulski, R.J. alpha V beta 5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82 (1999).
24. Qing, K. et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5, 71-77 (1999).
25. Samulski, R.J., Chang, L.S. & Shenk, T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61, 3096-3101 (1987).
26. Becerra, S.P., Koczot, F., Fabisch, P. & Rose, J.A. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J. Virol. 62, 2745-2754 (1988).
27. Opie, S.R., Warrington, K.H., Agbandje-McKenna, M., Zolotukhin, S. & Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995-7006 (2003).
28. Kern, A. et al. Identification of a heparin binding motif on AAV-2 capsids. J. Virol. (in the press).
29. Wobus, C.E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281-9293 (2000).
30. Moskalenko, M. et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74, 1761-1766 (2000).
31. Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052-10561, (1999).
32. Rabinowitz, J.E., Xiao, W.D. & Samulski, R.J. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265, 274-285 (1999).
33. Wu, P. et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647 (2000).
34. Shi, W.F., Arnold, G.S. & Bartlett, J.S. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697-1711 (2001).
35. Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Nat. Acad. Sci. USA 99, 10405-10410 (2002).
36. Li, J., Samulski, R.J. & Xiao, X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 71, 5236-5243 (1997).
37. Pajusola, K. et al. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J. Virol. 76, 11530-11540 (2002).
38. St. Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000).
39. Wu, Q. & Maniatis, T. A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell 197, 779-790 (1999).
40. Hauswirth, W.W., Lewin, A.S., Zolotukhin, S. & Muzyczka, N. Production and purification of recombinant adeno-associated virus. Meth. Enzymol. 316, 743-761 (2000).
41. Heilbronn, R., Burkle, A., Stephan, S, & zur Hausen, H. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J. Virol. 64, 3012-3018 (1990).
42. Xiao, X., Li, J. & Samulski, R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232 (1998).
43. Dubielzig, R., King, J.A., Weger, S., Kern, A. & Kleinschmidt, J.A. Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J. Virol. 73, 8989-8998 (1999).
44. Grimm, D. et al. Titration of AAV-2 particles via 6 novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322-1330 (1999).
45. Weger, S., Wistuba, A., Grimm, D. & Kleinschmidt, J.A. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins. J. Virol. 71, 8437-8447 (1997).
46. Zolotukhin, S., Potter, M., Hauswirth, W.W., Guy, J. & Muzyczka, N. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol. 70, 4646-4654 (1996).